MaaT Pharma Share Price Rises on Positive Clinical Trial Results

MaaT Pharma experienced a significant surge in its share price, climbing over 19% on the Paris Bourse, following the announcement of the success of its Phase 3 clinical trial for MaaT013 in treating acute graft-versus-host disease (aGvH). The study met its primary endpoint with a 62% overall gastrointestinal response rate at day 28, surpassing the expected 38% response rate. This 'unprecedented' level of efficacy has led analysts to increase the product's probability of success from 80% to 95% and raise the price target from 21 to 22 euros. MaaT013 aims to restore the symbiotic relationship between the patient's gut microbiota and immune system, improving long-term survival rates in 3rd-line GI-aGvH. The biotech company plans to file a marketing authorization application in Europe by mid-2025, ahead of schedule.